Article

Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae

  • Nature Microbiology 1, Article number: 16053 (2016)
  • doi:10.1038/nmicrobiol.2016.53
  • Download Citation
Received:
Accepted:
Published online:

Abstract

Antibiotic resistance is a major public health threat, further complicated by unexplained treatment failures caused by bacteria that appear antibiotic susceptible. We describe an Enterobacter cloacae isolate harbouring a minor subpopulation that is highly resistant to the last-line antibiotic colistin. This subpopulation was distinct from persisters, became predominant in colistin, returned to baseline after colistin removal and was dependent on the histidine kinase PhoQ. During murine infection, but in the absence of colistin, innate immune defences led to an increased frequency of the resistant subpopulation, leading to inefficacy of subsequent colistin therapy. An isolate with a lower-frequency colistin-resistant subpopulation similarly caused treatment failure but was misclassified as susceptible by current diagnostics once cultured outside the host. These data demonstrate the ability of low-frequency bacterial subpopulations to contribute to clinically relevant antibiotic resistance, elucidating an enigmatic cause of antibiotic treatment failure and highlighting the critical need for more sensitive diagnostics.

  • Subscribe to Nature Microbiology for full access:

    $59

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    United States Centers for Disease Control and Prevention Antibiotic Resistance Threats in the United States (2013);

  2. 2.

    Review on Antimicrobial Resistance Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations (2014);

  3. 3.

    , & Enterobacter cloacae complex: clinical impact and emerging antibiotic resistance. Future Microbiol. 7, 887–902 (2012).

  4. 4.

    & Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment. Front Microbiol. 6, 392 (2015).

  5. 5.

    & Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin. Microbiol. Rev. 10, 220–241 (1997).

  6. 6.

    & Antibacterial agents: back to the future? Can we live with only colistin, co-trimoxazole and fosfomycin? Clin. Microbiol. Infect. 18, 1–3 (2012).

  7. 7.

    & Colistin in the 21st century. Curr. Opin. Infect. Dis. 22, 535–543 (2009).

  8. 8.

    et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int. J. Antimicrob. Agents. 37, 415–419 (2011).

  9. 9.

    , , & Antimicrobial susceptibility testing: a primer for clinicians. Pharmacotherapy 29, 1326–1343 (2009).

  10. 10.

    , , & Colistin heteroresistance in enterobacter cloacae is associated with cross-resistance to the host antimicrobial lysozyme. Antimicrob. Agents Chemother. 58, 5594–5597 (2014).

  11. 11.

    et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science 339, 91–95 (2013).

  12. 12.

    et al. Phenotypic variation of Salmonella in host tissues delays eradication by antimicrobial chemotherapy. Cell 158, 722–733 (2014).

  13. 13.

    et al. Cecum lymph node dendritic cells harbor slow-growing bacteria phenotypically tolerant to antibiotic treatment. PLoS Biol. 12, e1001793 (2014).

  14. 14.

    Recognition of microorganisms and activation of the immune response. Nature 449, 819–826 (2007).

  15. 15.

    The liposome-mediated macrophage ‘suicide’ technique. J. Immunol. Methods 124, 1–6 (1989).

  16. 16.

    Mechanisms of macrophage antimicrobial activity. Trans. R. Soc. Trop. Med. Hyg. 77, 620–630 (1983).

  17. 17.

    & Macrophage signaling and respiratory burst. Immunol. Res. 26, 95–105 (2002).

  18. 18.

    et al. Identification and molecular characterization of the Mg2+ stimulon of Escherichia coli. J. Bacteriol. 185, 3696–3702 (2003).

  19. 19.

    , , & Salmonella typhimurium activates virulence gene transcription within acidified macrophage phagosomes. Proc. Natl Acad. Sci. USA 89, 10079–10083 (1992).

  20. 20.

    et al. Dissecting the PhoP regulatory network of Escherichia coli and Salmonella enterica. Proc. Natl Acad. Sci. USA 102, 2862–2867 (2005).

  21. 21.

    , , & Resolvase—in vivo expression technology analysis of the Salmonella enterica serovar Typhimurium PhoP and PmrA regulons in BALB/c mice. J. Bacteriol. 187, 7407–7416 (2005).

  22. 22.

    et al. Serratia marcescens arn, a PhoP-regulated locus necessary for polymyxin B resistance. Antimicrob. Agents Chemother. 58, 5181–5190 (2014).

  23. 23.

    et al. Comparison of the PhoPQ regulon in Escherichia coli and Salmonella typhimurium. J. Mol. Evol. 60, 462–474 (2005).

  24. 24.

    et al. Transcriptome analysis of all two-component regulatory system mutants of Escherichia coli K-12. Mol. Microbiol. 46, 281–291 (2002).

  25. 25.

    , & Activated by different signals, the PhoP/PhoQ two-component system differentially regulates metal uptake. J. Bacteriol. 191, 7174–7181 (2009).

  26. 26.

    & Mechanisms of antimicrobial peptide resistance in Gram-negative bacteria. Antibiotics (Basel) 4, 18–41 (2015).

  27. 27.

    , , & Lipid A modification systems in Gram-negative bacteria. Annu. Rev. Biochem. 76, 295–329 (2007).

  28. 28.

    , , & Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. mBio 2, e00100–e00111 (2011).

  29. 29.

    et al. Internalization of Salmonella by macrophages induces formation of nonreplicating persisters. Science 343, 204–208 (2014).

  30. 30.

    & Mode of action of streptomycin on type B Hemophilus influenzae: II. Nature of resistant variants. J. Exp. Med. 85, 607–621 (1947).

  31. 31.

    Hetero-resistance: an under-recognised confounder in diagnosis and therapy? J. Med. Microbiol. 50, 1018–1020 (2001).

  32. 32.

    et al. Mixed infections and rifampin heteroresistance among mycobacterium tuberculosis clinical isolates. J. Clin. Microbiol. 53, 2138–2147 (2015).

  33. 33.

    & Antimicrobial heteroresistance: an emerging field in need of clarity. Clin. Microbiol. Rev. 28, 191–207 (2015).

  34. 34.

    et al. Heteroresistance of Helicobacter pylori from the same patient prior to antibiotic treatment. Infect. Genet. Evol. 23, 196–202 (2014).

  35. 35.

    et al. New vector tools with a hygromycin resistance marker for use with opportunistic pathogens. Mol. Biotechnol. 48, 7–14 (2011).

  36. 36.

    , , , & Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77, 61–68 (1989).

  37. 37.

    & An improved system for gene replacement and xylE fusion analysis in Pseudomonas aeruginosa. Gene 158, 15–22 (1995).

  38. 38.

    & Rational design of a plasmid origin that replicates efficiently in both gram-positive and gram-negative bacteria. PLoS ONE 5, e13244 (2010).

  39. 39.

    Applied Biosystems. TRI Reagent Solution RNA/DNA/Protein Isolation Reagent Manual (Ambion, 2010).

  40. 40.

    et al. Hybrid error correction and de novo assembly of single-molecule sequencing reads. Nature Biotechnol. 30, 693–700 (2012).

  41. 41.

    , , & ALE: a generic assembly likelihood evaluation framework for assessing the accuracy of genome and metagenome assemblies. Bioinformatics 29, 435–443 (2013).

  42. 42.

    & Fast and accurate long-read alignment with Burrows–Wheeler transform. Bioinformatics 26, 589–595 (2010).

  43. 43.

    et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).

  44. 44.

    , , & Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).

  45. 45.

    , , & Identification of novel transcripts in annotated genomes using RNA-Seq. Bioinformatics 27, 2325–2329 (2011).

  46. 46.

    et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature Protoc. 7, 562–578 (2012).

  47. 47.

    et al. High-throughput functional annotation and data mining with the Blast2GO suite. Nucleic Acids Res. 36, 3420–3435 (2008).

  48. 48.

    , & Irreproducible and uninterpretable polymyxin B MICs for Enterobacter cloacae and Enterobacter aerogenes. J. Clin. Microbiol. 51, 4106–4111 (2013).

  49. 49.

    & Analyzing real-time PCR data by the comparative C(T) method. Nature Protoc. 3, 1101–1108 (2008).

  50. 50.

    , & Activation of PmrA inhibits LpxT-dependent phosphorylation of lipid A promoting resistance to antimicrobial peptides. Mol. Microbiol. 76, 1444–1460 (2010).

Download references

Acknowledgements

The authors thank S. Satola, M. Farley and the Georgia Emerging Infections Program for providing Enterobacter cloacae strains Mu117, Mu819 and R/S-lo, P. Rather for providing plasmid pMQ310, the Yerkes Nonhuman Primate Genomics Core for help with DNA sequencing and analysis, and C.-Y. Chin and D. Bonenberger for breeding and genotyping knockout mice. The authors also thank R. Ahmed, A. Grakoui and W. Shafer for comments and revisions of the manuscript. D.S.W. is supported by a Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Disease award, VA Merit Award I01 BX002788 and National Institutes of Health (NIH) grant AI098800. E.K.C. is supported by the National Institute of Allergy and Infectious Diseases of the NIH under award no. T32AI106699. M.S.T. is supported by the NIH (grants nos RO1AI064184, RO1AI76322 and R21AI11987) and the Army Research Office (grant no. 61789-MA-MUR). T.D.R. and K.V. were supported by 1U01CI000906-05 ‘Emerging Infections Program (EIP) PPACA: Enhancing Epidemiology and Laboratory Capacity’ funding from the Emory Public Health Bioinformatics Fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the Department of Veterans Affairs or the Centers for Disease Control and Prevention.

Author information

Author notes

    • Victor I. Band
    •  & Emily K. Crispell

    These authors contributed equally to this work.

Affiliations

  1. Department of Microbiology and Immunology, Emory University, Atlanta, Georgia 30329, USA

    • Victor I. Band
    • , Emily K. Crispell
    • , Brooke A. Napier
    •  & Steven E. Bosinger
  2. Emory Vaccine Center, Atlanta, Georgia 30329, USA

    • Victor I. Band
    • , Emily K. Crispell
    • , Brooke A. Napier
    • , Steven E. Bosinger
    •  & David S. Weiss
  3. Department of Infectious Disease, College of Veterinary Medicine, University of Georgia, Athens, Georgia 30602 USA

    • Carmen M. Herrera
    •  & M. Stephen Trent
  4. Non-Human Primate Genomics Core, Yerkes National Primate Research Center, Robert W. Woodruff Health Sciences Center, Emory University, Atlanta, Georgia 30322, USA

    • Greg K. Tharp
    •  & Steven E. Bosinger
  5. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA

    • Kranthi Vavikolanu
    • , Timothy D. Read
    • , Eileen M. Burd
    •  & David S. Weiss
  6. Biotechnology Core Facility Branch, Centers for Disease Control, Atlanta, Georgia 30333, USA

    • Jan Pohl
  7. Emory Antibiotic Resistance Center, Atlanta, Georgia 30329, USA

    • Timothy D. Read
    • , Eileen M. Burd
    •  & David S. Weiss
  8. Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia 30322, USA

    • Timothy D. Read
  9. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia 30322, USA

    • Eileen M. Burd
  10. Research Service, Atlanta VA Medical Center, Decatur, Georgia 30033, USA

    • David S. Weiss

Authors

  1. Search for Victor I. Band in:

  2. Search for Emily K. Crispell in:

  3. Search for Brooke A. Napier in:

  4. Search for Carmen M. Herrera in:

  5. Search for Greg K. Tharp in:

  6. Search for Kranthi Vavikolanu in:

  7. Search for Jan Pohl in:

  8. Search for Timothy D. Read in:

  9. Search for Steven E. Bosinger in:

  10. Search for M. Stephen Trent in:

  11. Search for Eileen M. Burd in:

  12. Search for David S. Weiss in:

Contributions

Experiments were conducted by V.I.B., E.K.C. and B.A.N. The manuscript was prepared by V.I.B., E.K.C. and D.S.W. Clinical microbiological assays were conducted by E.M.B., who also provided the R/S strain. Lipid A analysis was performed by C.M.H. and M.S.T. Sequence analysis was performed by E.K.C., G.K.T., K.V., T.D.R. and S.E.B. J.P. synthesized and purified host antimicrobials. The study was planned and directed by D.S.W.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to David S. Weiss.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Supplementary Figures 1–24

Excel files

  1. 1.

    Supplementary Data

    Supplementary Tables 1–4